FDA Approves the First 100% Effective HIV‑Preventive Drug in the United States

On 18 June, the United States Food and Drug Administration (FDA) granted its first-ever approval of an HIV‑preventive medication, “YesToGo” (lenacapavir)—a milestone offering nearly 100 per cent (99.99 %) protection against HIV with just two injections per year.

For almost four decades, the global HIV pandemic has claimed millions of lives. This breakthrough medicine may now hold the promise of saving countless more.

What Is Lenacapavir and How It Works

• Lenacapavir is a capsid‑inhibitor, targeting the HIV‑1 virus by disrupting the protein shell that protects the virus’s genetic material, preventing viral replication.
• It serves as a pre‑exposure prophylaxis (PrEP) for HIV‑negative individuals, delivering around 99 per cent protection from infection.
• It does not require daily dosing—just two injections annually, addressing adherence issues associated with oral PrEP.

In 2024, the journal Science named lenacapavir “Breakthrough of the Year”, and subsequent trials have confirmed its outstanding efficacy.

Developer and Access Strategy

Gilead Sciences, the maker of the drug, has begun global efforts to ensure affordable access:

• Signed royalty‑free licence agreements with six generic manufacturers, enabling low‑cost production for global distribution.
• Plans to supply 2 million free doses over three years in collaboration with the Global Fund, targeting uninsured, eligible populations.
• Will launch an Advancing Access Programme, allowing qualifying uninsured individuals to receive the injections at no cost.
• Has applied for regulatory approval in Australia, Brazil, Canada, South Africa, and Switzerland, with applications forthcoming in Argentina, Mexico, and Peru.

From Treatment to Prevention

• Initially approved in 2022 under the brand name Sunlenca for treating existing HIV patients.
• Now, it will be used for long‑term HIV prevention, extending its life‑saving potential significantly.

Expert Opinions

• Daniel O’Day, Chairman and CEO of Gilead, dubbed the day of approval a “historic moment” in the fight against HIV, calling YesToGo one of the most significant scientific achievements of our time.
• Dr Carlos del Rio of Emory University School of Medicine emphasised that the twice‑annual injection could encourage uptake of PrEP, especially among those hesitant about daily pills due to stigma or inconvenience.

Global Impact

Peter Sands, Executive Director of the Global Fund, described YesToGo as not merely a scientific triumph but a game‑changer in HIV/AIDS prevention, offering a tool that may transform the course of the pandemic.

With FDA approval on 18 June, lenacapavir marks a pivotal advance in global HIV prevention—bringing hope for a future where HIV becomes a preventable disease for millions.

Source: New Atlas